Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer. A systematic review and meta-analysis
01 Pubblicazione su rivista
Maggi M., Panebianco V., Mosca A., Salciccia S., Gentilucci A., Di Pierro G., Busetto G. M., Barchetti G., Campa R., Sperduti I., Del Giudice F., Sciarra A.
ISSN: 2405-4569
In the Prostate Imaging Reporting and Data System (PI-RADS) 3 population, the overall detection rates for prostate cancer (PC) and clinically significant PC (csPC) range from 10.3% to 55.8% and from 3.4% to 46.5%, respectively. Decision to perform only a targeted biopsy or a systematic biopsy should be associated with a lower detection rate of both PC and csPC. PI-RADS v1 or v2 seems to have no significant impact on biopsy outcomes. A prostate-specific antigen density of ≥0.15 ng/ml/ml may represent an index to decide whether to biopsy or not.